Ultra-low-dose estrogen therapy for female hypogonadism

Hasegawa, Yukihiro; Itonaga, Tomoyo; Ikegawa, Kento; Nishigaki, Satsuki; Kawai, Masanobu; Koga, Eri; Sakakibara, Hideya; Ross, Judith L.

doi:10.1297/cpe.29.49

Cited by 4 publications

(4 citation statements)

References 11 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This section discusses the rationale for ideal E2-TD therapy in greater detail than our previous publications on the topic [( 77 , 78 ) as an erratum of 79]. The rationale of pubertal induction for TS without endogenous ovarian function includes the following:…”

Section: Our Suggestions For Ideal Pubertal Inductionmentioning

confidence: 99%

Pubertal induction in Turner syndrome without gonadal function: A possibility of earlier, lower-dose estrogen therapy

Hasegawa

Satoh

et al. 2023

Front. Endocrinol.

Self Cite

View full text Add to dashboard Cite

Delayed and absent puberty and infertility in Turner syndrome (TS) are caused by primary hypogonadism. A majority of patients with TS who are followed at hospitals during childhood will not experience regular menstruation. In fact, almost all patients with TS need estrogen replacement therapy (ERT) before they are young adults. ERT in TS is administered empirically. However, some practical issues concerning puberty induction in TS require clarification, such as how early to start ERT. The present monograph aims to review current pubertal induction therapies for TS without endogenous estrogen production and suggests a new therapeutic approach using a transdermal estradiol patch that mimics incremental increases in circulating, physiological estradiol. Although evidence supporting this approach is still scarce, pubertal induction with earlier, lower-dose estrogen therapy more closely approximates endogenous estradiol secretion.

show abstract

Section: Our Suggestions For Ideal Pubertal Inductionmentioning

confidence: 99%

Pubertal induction in Turner syndrome without gonadal function: A possibility of earlier, lower-dose estrogen therapy

Hasegawa

Satoh

et al. 2023

Front. Endocrinol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Many research findings have supported the idea that EE2 might have certain negative consequences, including headaches, breast tenderness, nausea, dizziness, and weight gain. Therefore, EE2 is often advised for oral administration at a lower doses to avoid its side effects [48,49].…”

Section: Biological Functions and Applications Of Estrogens As Therap...mentioning

confidence: 99%

A Review on Cyclodextrins/Estrogens Inclusion Complexes

Araj,

Szeleszczuk

2023

IJMS

View full text Add to dashboard Cite

This review focuses on the methods of preparation and biological, physiochemical, and theoretical analysis of the inclusion complexes formed between estrogens and cyclodextrins (CDs). Because estrogens have a low polarity, they can interact with some cyclodextrins’ hydrophobic cavities to create inclusion complexes, if their geometric properties are compatible. For the last forty years, estrogen-CD complexes have been widely applied in several fields for various objectives. For example, CDs have been used as estrogen solubilizers and absorption boosters in pharmaceutical formulations, as well as in chromatographic and electrophoretic procedures for their separation and quantification. Other applications include the removal of the endocrine disruptors from environmental materials, the preparation of the samples for mass spectrometric analysis, or solid-phase extractions based on complex formation with CDs. The aim of this review is to gather the most important outcomes from the works related to this topic, presenting the results of synthesis, in silico, in vitro, and in vivo analysis.

show abstract

“…At the beginning of menopause, the production of estrogen drops significantly and thus leads to well-known symptoms in women in this phase of life [166]. Bone health, heart health, female fertility, various regulatory effects on glucose metabolism, the maintenance of immune function, nerve function and the role of estrogens in the treatment of many pathologies are also modulated by estrogen signaling [114,[127][128][129][166][167][168][169][170][171][172][173][174][175][176][177][178][179][180][181]. The estrogen circulating in the woman's body acts in an endocrine, paracrine or intracrine manner and binds to the three most important of its receptors, the estrogen receptor α (ERα), the estrogen receptor β (ERβ) or the G protein-coupled estrogen receptor 1 (GPER1) [182,183].…”

Section: General Information About Sex Steroid Hormones Their Biosynt...mentioning

confidence: 99%

Like Brothers in Arms: How Hormonal Stimuli and Changes in the Metabolism Signaling Cooperate, Leading HPV Infection to Drive the Onset of Cervical Cancer

Läsche

Gallwas

Gründker

2022

IJMS

View full text Add to dashboard Cite

Despite all precautionary actions and the possibility of using vaccinations to counteract infections caused by human papillomaviruses (HPVs), HPV-related cancers still account for approximately 5% of all carcinomas. Worldwide, many women are still excluded from adequate health care due to their social position and origin. Therefore, immense efforts in research and therapy are still required to counteract the challenges that this disease entails. The special thing about an HPV infection is that it is not only able to trick the immune system in a sophisticated way, but also, through genetic integration into the host genome, to use all the resources available to the host cells to complete the replication cycle of the virus without activating the alarm mechanisms of immune recognition and elimination. The mechanisms utilized by the virus are the metabolic, immune, and hormonal signaling pathways that it manipulates. Since the virus is dependent on replication enzymes of the host cells, it also intervenes in the cell cycle of the differentiating keratinocytes and shifts their terminal differentiation to the uppermost layers of the squamocolumnar transformation zone (TZ) of the cervix. The individual signaling pathways are closely related and equally important not only for the successful replication of the virus but also for the onset of cervical cancer. We will therefore analyze the effects of HPV infection on metabolic signaling, as well as changes in hormonal and immune signaling in the tumor and its microenvironment to understand how each level of signaling interacts to promote tumorigenesis of cervical cancer.

show abstract

Ultra-low-dose estrogen therapy for female hypogonadism

Cited by 4 publications

References 11 publications

Pubertal induction in Turner syndrome without gonadal function: A possibility of earlier, lower-dose estrogen therapy

Pubertal induction in Turner syndrome without gonadal function: A possibility of earlier, lower-dose estrogen therapy

A Review on Cyclodextrins/Estrogens Inclusion Complexes

Like Brothers in Arms: How Hormonal Stimuli and Changes in the Metabolism Signaling Cooperate, Leading HPV Infection to Drive the Onset of Cervical Cancer

Contact Info

Product

Resources

About